抗肿瘤原位凝胶给药系统的研究进展  

Research progress of anti-tumor in situ gel delivery system

作　　者：肖聪聪 刘陈霏 冯靖 陈丽青[1] 赵鹤鸣 金明姬[1] 高钟镐[1] 黄伟[1] XIAO Cong-cong;LIU Chen-fei;FENG Jing;CHEN Li-qing;ZHAO He-ming;JIN Ming-ji;GAO Zhong-gao;HUANG Wei(Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China)

机构地区：[1]中国医学科学院,北京协和医学院药物研究所,药物传输技术与新型制剂北京市重点实验室,北京100050

出　　处：《药学学报》2023年第10期3004-3015,共12页Acta Pharmaceutica Sinica

基　　金：中国医学科学院医学与健康创新工程重大协同创新项目(2021-I2M-1-026)。

摘　　要：癌症是导致全世界死亡的主要原因之一,2020年约1000万死亡病例由癌症导致。原位凝胶给药系统具有良好的组织相容性、优良的可注射性、高载药量、可缓释给药及受体内环境影响较小等优点,在药剂学与生物技术领域备受关注。原位凝胶可以结合化疗、光热治疗、化学动力学治疗、免疫治疗等多种治疗方法,可在无需外科手术的情况下,以较小的侵入方式将药物递送进肿瘤部位,形成半固体凝胶状态的药物贮库,实现肿瘤原位联合治疗。本文汇总了近10年来抗肿瘤原位凝胶给药系统的研究进展,介绍了其常用高分子材料、分类原理及具体应用实例,最后对关键性问题进行了总结和讨论,以期为未来新型抗肿瘤给药系统的开发提供参考。Cancer is the most important leading cause of death worldwide,with about 10 million deaths caused by cancer in 2020.In situ gel drug delivery systems have attracted much attention in the field of pharmacy and biotechnology due to their good histo-compatibility,excellent injectability,high drug delivery capacity,slow-release drug delivery,and less influence by the in vivo environment.Meanwhile,in situ gel can be combined with chemotherapy,photo-thermal therapy,chemokinetic therapy,immunotherapy and so on to deliver drugs into the tumor site in a less invasive way without surgical operation,forming a semi-solid gel reservoir in the tumor site to realize in situ tumor combined therapy.In this paper,the author summarized the research progress of anti-tumor in situ gel delivery system in the past 10 years,introduced its commonly used polymer materials,classification principles and specific application examples,and finally summarized and discussed the key issues,in order to provide reference for the development of new anti-tumor drug delivery system in the future.

关 键 词：原位凝胶 给药系统 癌症 抗肿瘤 联合治疗 

分 类 号：R943[医药卫生—药剂学]